The largest is the retrospective cohort study by Kutz et al., which included a total of 744,310 older patients ≥65 years of age with type 2 diabetes mellitus, to compare the cardiovascular effectiveness and safety of SGLT-2 inhibitors and GLP-1RA according to frailty status. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.